Idogen AB, a Ventac Portfolio company, reports that the company has made a breakthrough in the development of the company’s tolerogenic vaccine. Idogen has now in a proof-of-concept study shown that the company’s technology successfully has been confirmed in human cells. These positive results represent an important step in the development of a tolerogenic vaccine and an important step closer to treating patients with severe hemophilia A affected by factor VIII antibodies. For more information, please follow this link.
We participate in numerous events promoting our portfolio companies and meeting our clients.
Ventac Partners is very excited to announce its latest portfolio company, Orbit Genomics, focused on often ignored micro-satellites (short repeat sequences of DNA) as a diagnostic tool. Orbit’s first indication will be on brain cancer. Additional applications will include other cancer and non-cancer indications as well as a new tool for companion diagnostics. For more information, please visit www.orbitgenomics.com.
Copenhagen office has a new associate partner. Golnaz Borghei, a PhD holder from Cambridge University, brings several years of experience in research/industry interface and consulting in Europe and the Middle East.
Ventac Partners has permanently established offices in California. Scott Woodward, having spent the last 5 years in Europe at our Copenhagen office, is returning to the United States to lead activities in San Francisco beginning August 01. He will be joined by our newest partner, Randy Berholtz in San Diego. Randy has been involved in the San Diego life science community in various leadership, legal, and funding roles for almost 20 years. Complete bios for both, as well as for all other partners. This gives us a strong footprint in the world’s oldest and largest life science cluster in Northern California and also in the fast growing areas of San Diego and Los Angeles/Orange County. Both will also work closely with our existing partners in Boston, Boulder, and New York.
Ventac Partner has a new office in Trondheim. Ventac US partner, Aarti Kapoor, has moved from US to Norway, to set up Ventac Partners office in Trondheim.
News from our strategic partners Clinical Network Services (CNS). CNS has expanded its BioDesk Service into Washington D.C. to support clients engaging with the FDA. BioDesk is an expert team offering CMC/manufacturing, toxicology, clinical and regulatory affairs consulting services for readying products to enter clinical trials or marketing approval. Read more
RhoVac, a Ventac Partners portfolio company, receives subscriptions for USD 17 million in preparation of its listing on the Swedish stock exchange AktieTorget. First day of trading has been set for March 9, 2016. For more information, please visit www.rhovac.com (in Swedish).
Idogen, a Ventac Partners portfolio company, published year-end report for the period January to December 2015, see www.idogen.se for more details.